Document is current
Any future updates will be listed below
-
Authors
Björk, Johannes R. https://orcid.org/0000-0001-9768-1946
Bolte, Laura A. https://orcid.org/0000-0001-6036-0831
Maltez Thomas, Andrew https://orcid.org/0000-0001-5789-3354
Lee, Karla A.
Rossi, Niccolo
Wind, Thijs T.
Smit, Lotte M.
Armanini, Federica
Asnicar, Francesco https://orcid.org/0000-0003-3732-1468
Blanco-Miguez, Aitor https://orcid.org/0000-0001-7386-5572
Board, Ruth
Calbet-Llopart, Neus
Derosa, Lisa https://orcid.org/0000-0003-0527-2964
Dhomen, Nathalie https://orcid.org/0000-0003-1961-2173
Brooks, Kelly
Harland, Mark
Harries, Mark
Lorigan, Paul
Manghi, Paolo
Marais, Richard
Newton-Bishop, Julia
Nezi, Luigi https://orcid.org/0000-0002-4670-7656
Pinto, Federica https://orcid.org/0000-0002-4539-4811
Potrony, Miriam
Puig, Susana https://orcid.org/0000-0003-1337-9745
Serra-Bellver, Patricio
Shaw, Heather M.
Tamburini, Sabrina
Valpione, Sara
Waldron, Levi https://orcid.org/0000-0003-2725-0694
Zitvogel, Laurence https://orcid.org/0000-0003-1596-0998
Zolfo, Moreno
de Vries, Elisabeth G. E. https://orcid.org/0000-0002-8949-7425
Nathan, Paul
Fehrmann, Rudolf S. N. https://orcid.org/0000-0002-7516-315X
Spector, Tim D.
Bataille, Véronique
Segata, Nicola
Hospers, Geke A. P. https://orcid.org/0000-0002-3047-7892
Weersma, Rinse K. https://orcid.org/0000-0001-7928-7371
- License Information
-
More Information
Article History
Received: 20 June 2023
Accepted: 3 January 2024
First Online: 16 February 2024
Competing interests
: R.K.W. acted as a consultant for Takeda; received unrestricted research grants from Takeda, Johnson & Johnson, Tramedico and Ferring; and received speaker fees from MSD, AbbVie and Janssen Pharmaceuticals. E.G.E.d.V. reports an advisory role at Daiichi Sankyo, NSABP and Sanofi (paid to University Medical Center Groningen) and research funding from Amgen, AstraZeneca, Bayer, Chugai Pharma, CytomX Therapeutics, G1 Therapeutics, Genentech, Nordic Nanovector, Radius Health, Regeneron, Roche, Servier and Synthon (paid to University Medical Center Groningen). S.P. received speaker fees from Almirall, BMS, ISDIN, La Roche Posay, Leo Pharma, Regeneron, Roche and Sanofi; acted as advisory board member of Almirall, ISDIN, La Roche Posay, Pfizer, Roche, Regeneron, Sanofi and Sun Pharma; and received research funding from Abbie, AMGEN, ISDIN, La Roche Posay, Leo Pharma and Novartis. R.B. has received honoraria from, and sits on advisory boards of, Novartis, BMS and MSD. The other authors declare no competing interests.
